Results 171 to 180 of about 31,215 (290)

Diabetes management in people undergoing metabolic‐bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP) Group

Diabetic Medicine, Volume 43, Issue 5, May 2026.
Abstract The global prevalence of obesity and diabetes continues to rise, with metabolic‐bariatric surgery recognised as an effective intervention for obesity and type 2 diabetes, offering potential for type 2 diabetes remission and improved glycaemic control. This guideline, developed by the Joint British Diabetes Societies for Inpatient Care (JBDS‐IP)
Jeffrey W. Stephens, Ketan Dhatariya, Andrew J. Beamish, Dimitri J. Pournaras, Alexander D. Miras, Nader Raafat, Georgia Noble‐Bell, Rachel Cadwallader Buckland, Omar G. Mustafa   +8 more
wiley   +1 more source

Comparative Analysis of Clinical Outcomes in Patients With Type 2 Diabetes Mellitus on Monotherapy Versus Combination Therapy. [PDF]

Cureus
Mahapatra H, Gupta PK, Paul A, Nampalliwar A, Bansal M, Das B, Namboothiri KP.   +6 more
europepmc   +1 more source

Retraction: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Hepatic and abdominal adiposity in type 2 diabetes as assessed with machine learning on computed tomography scans

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3742-3751, May 2026.
Abstract Aims The combined assessment of multiple abdominal imaging traits in relation to type 2 diabetes remains incompletely characterised. The study examines these relationships on computed tomography (CT) scans from a large‐scale, racially diverse, disease‐focused medical biobank.
Richard H. Tran, Pavan Raghupathy, Mohamad Hazim, Elizabeth Thompson, Sophia Swago, Abhijit Bhattaru, Matthew MacLean, Jeffrey T. Duda, James Gee, Charles Kahn Jr., Daniel J. Rader, Arijitt Borthakur, Walter R. Witschey, Hersh Sagreiya   +13 more
wiley   +1 more source

Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data. [PDF]

J Cachexia Sarcopenia Muscle
Ueta S, Niimura T, Goda M, Ishida T, Iwata N, Takeda T, Kawada K, Miyata K, Aizawa F, Yagi K, Hamano H, Chuma M, Izawa-Ishizawa Y, Zamami Y, Ishizawa K.   +14 more
europepmc   +1 more source

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3807-3818, May 2026.
Abstract Aims To investigate the association between sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2i) and obesity‐associated cancers (OAC) in individuals with type 2 diabetes (T2D). Materials and Methods This retrospective cohort study used data from the TriNetX US Collaborative Network.
Testimony Ipaye, Jonathan Goldney, Thomas Yates, Francesco Zaccardi, Kamlesh Khunti, Elina Akalestou, Melanie J. Davies, Karen Brown, Dimitris Papamargaritis   +8 more
wiley   +1 more source

Subtype-Specific Causal Effects of Antidiabetic Drug Targets on Ovarian Cancer: Mendelian Randomization and Colocalization Evidence. [PDF]

Int J Womens Health
Tang E, Zeng J, Shi X, Wang Y, Sun Y, Wu L.   +5 more
europepmc   +1 more source

Associations of obesity, systemic inflammation, and hyperinsulinemia with the incidence of non‐communicable chronic disease and mortality: A prospective cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3883-3894, May 2026.
Abstract Aims Obesity, systemic inflammation, and hyperinsulinemia are all features of metabolic syndrome and frequently occur together. We aimed to evaluate the association of body mass index (BMI) with incident non‐communicable chronic disease (NCD) or all‐cause mortality, independent of C‐reactive protein (CRP) and fasting insulin.
Natasha Wiebe, Stephanie Thompson, Peter Stenvinkel, Aminu Bello, Matthew T. James, Marcello Tonelli   +5 more
wiley   +1 more source

GLP-1RAs: antidiabetic drug crossover-new hope for chronic inflammatory airway diseases. [PDF]

Respir Res
Chen Y, Shen Y, Shen H, Liu Z.
europepmc   +1 more source

Sustained glucagon‐like peptide‐1 receptor agonist treatment improves glycemic control and reduces all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitors: A real‐world target trial emulation in type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3974-3984, May 2026.
Abstract Background Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) improve glycemic outcomes in people with type 2 diabetes, but their generalizability to routine clinical practice remains uncertain. Aim To evaluate the real‐world effectiveness of sustained GLP‐1 RA use on haemoglobin A1c (HbA1c) over 1 to 4.5 years, using dipeptidyl peptidase 4
Kathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, Hannah Karin Wood‐Kurland, Ulrik Pedersen‐Bjergaard, Mikkel Porsborg Andersen, Jens Michelsen, Henrik Imberg, Marcus Lind, Sara Hallström, Stefanie Lanzinger, Anders Munch, Johan Sebastian Ohlendorff, Thomas Alexander Gerds, Christian Torp‐Pedersen, The REDDIE Consortium   +15 more
wiley   +1 more source